BLA 761163 · Morphosys US INC
Monjuvi
Tafasitamab-Cxix · Intravenous
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Jun 18, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Jul 31, 2020
Approved uses
2
Original approval plus efficacy supplements
Registered trials
58
6 Phase 3, 21 recruiting
FAERS reports
906
665 serious, 131 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 2, 2026.
MONJUVI, in combination with lenalidomide, is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). This indication is approved under accelerated approval based on overall response rate [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). MONJUVI is a CD19-directed cytolytic antibody indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1 )
Mechanism: Tafasitamab-cxix is an Fc-modified monoclonal antibody that binds to CD19 antigen expressed on the surface of pre-B and mature B lymphocytes and on several B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL). Upon binding to CD19, tafasitamab-cxix mediates B-cell lysis through apoptosis and immune effector mechanisms, including antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). In studies conducted in vitro in DLBCL tumor cells, tafasitamab-cxix in combination with lenalidomide resulted in increased ADCC activity compared to...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 18, 2025 Supplement 13 · Efficacy · priority review OrphanLabelLetter
- Jul 31, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelLetterReview
1 products under this application
- MONJUVI · TAFASITAMAB-CXIX 12MG/KG · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Tafasitamab" as an intervention, any sponsor and status, largest first.
- Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL PatientsPivotal-lookingActive, not recruiting
Incyte CorporationIncyte (INCY)
NCT04824092 · 899 participants · Start May 11, 2021 · Primary completion Sep 1, 2026
Drug: Tafasitamab; Lenalidomide and 7 more · For: Diffuse Large B-cell Lymphoma
Sites: Daphne, Alabama; Anaheim, California; Clovis, California · 307 sites in all
- A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.Pivotal-lookingActive, not recruiting
Incyte CorporationIncyte (INCY)
NCT04680052 · 654 participants · Start Apr 15, 2021 · Primary completion Feb 23, 2024
Drug: tafasitamab; rituximab and 2 more · For: Follicular Lymphoma; Marginal Zone Lymphoma
Sites: Concord, California; Greenbrae, California; Pasadena, California · 261 sites in all
- A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)Pivotal-lookingNot yet recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07917754 · 470 participants (planned) · Start Dec 13, 2026 · Primary completion Mar 13, 2037
Drug: MK-1045; Zilovertamab vedotin and 8 more · For: Lymphoma, Large B-Cell, Diffuse; Diffuse Large B-Cell Lymphoma
- A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)Pivotal-lookingCompleted
Incyte CorporationIncyte (INCY)
NCT02763319 · 453 participants · Start Nov 28, 2016 · Primary completion Jun 21, 2024
Drug: Rituximab (RTX); Tafasitamab and 1 more · For: Diffuse Large B-cell Lymphoma
Sites: Anaheim, California; Bakersfield, California; Burbank, California · 158 sites in all
- A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)Active, not recruiting
CelgeneBristol Myers Squibb (BMY)
NCT03930953 · 438 participants (planned) · Start May 20, 2019 · Primary completion Apr 7, 2027
Drug: CC-99282; Rituximab and 3 more · For: Lymphoma, Non-Hodgkin
Sites: Scottsdale, Arizona; Jacksonville, Florida; Tampa, Florida · 66 sites in all
Beijing InnoCare Pharma Tech Co., Ltd.Industry
NCT06521255 · 244 participants (planned) · Start May 7, 2024 · Primary completion Sep 2028
Drug: Tafasitamab; Lenalidomide and 3 more · For: DLBCL
Sites: Beijing, China; Changchun, China; Changsha, China · 20 sites in all
- Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to TreatmentPivotal-lookingRecruiting
SWOG Cancer Research NetworkResearch network
NCT05890352 · 227 participants (planned) · Start Sep 26, 2023 · Primary completion Dec 1, 2029
Drug: Lenalidomide; Tafasitamab and 2 more · For: Grade 3b Follicular Lymphoma; High Grade B-Cell Lymphoma; High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements and 3 more
Sites: Tucson, Arizona; Beverly Hills, California; Duarte, California · 104 sites in all
Academic and Community Cancer Research UnitedAcademic, hospital or other
NCT05910801 · 100 participants (planned) · Start Jan 4, 2024 · Primary completion Dec 30, 2029
Drug: Lenalidomide; Tafasitamab and 1 more · For: Recurrent Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma
Sites: Rochester, Minnesota; Houston, Texas
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- disease progression239
- off label use168
- lymphoma165
- death66
- drug ineffective47
- diffuse large b-cell lymphoma42
- neutropenia39
- blood lactate dehydrogenase increased38
- malignant neoplasm progression38
- covid-1930
- polyneuropathy29
- diarrhoea28
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 12 |
| 2021 | 93 |
| 2022 | 179 |
| 2023 | 380 |
| 2024 | 135 |
| 2025 | 65 |
| 2026 | 42 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Monjuvi (Tafasitamab-Cxix)
2024 spending
$1.0M
Beneficiaries
14
75 claims
Per beneficiary
$74,016
$1,323.40 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $808,990 |
| 2022 | $312,555 |
| 2023 | $1,179,804 |
| 2024 | $1,036,223 |
Part B: Monjuvi (Tafasitamab-Cxix) · HCPCS J9349
2024 spending
$43.1M
Beneficiaries
545
5,980 claims
Per beneficiary
$79,155
2024 ASP limit $13.66 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $32,609,272 |
| 2022 | $47,897,377 |
| 2023 | $46,746,005 |
| 2024 | $43,139,723 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study.
Duell J, Abrisqueta P, Andre M, et al. · Haematologica 2024 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
- Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
Salles G, Duell J, González Barca E, et al. · Lancet Oncol 2020 · Clinical Trial, Phase II, Multicenter Study
- Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.
Sehn LH, Hübel K, Luminari S, et al. · Lancet 2026 · Clinical Trial, Phase III, Randomized Controlled Trial
- Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.
Lenz G, Trněný M, Burke JM, et al. · Lancet 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study.
Belada D, Kopeckova K, Bergua Burgues JM, et al. · Blood 2023 · Randomized Controlled Trial, Clinical Trial, Phase I
- Tafasitamab as Monotherapy or in Combination in Japanese Patients With B-Cell Non-Hodgkin Lymphoma: Results From the Phase 1b J-MIND Study.
Izutsu K, Fukuhara N, Yuda J, et al. · Cancer Sci 2026 · Clinical Trial, Phase I, Multicenter Study
Sponsor: Morphosys US INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.